Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands		3 Months Ended				6 Months Ended
	Jul. 04, 2025	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2025 USD ($) Segment	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash, cash equivalents and restricted cash, maturity period						three months or less
Net loss		$ (11,216)	$ (6,495)	$ (44,907)	$ (23,631)	$ (17,711)	$ (68,538)
Cash and cash equivalents and short-term investments		107,600				107,600
Working capital		97,700				97,700
Accumulated deficit		$ (373,297)				$ (373,297)		$ (355,586)
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]						srt:ChiefExecutiveOfficerMember
Segment Reporting, Factors Used to Identify Entity's Reportable Segments						The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company’s long-term company-wide strategic goals.
Number of operating segments \| Segment						1
Number of reportable segments \| Segment						1
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description						the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results.
Subsequent event
Summary Of Significant Accounting Policies [Line Items]
Percentage of bonus depreciation and domestic research cost	100.00%
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.
Summary Of Significant Accounting Policies [Line Items]
Ownership interest percentage						100.00%
Otic Pharma, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Ownership interest percentage						100.00%

Eledon Pharmaceuticals, Inc. 10-Q